Retinitis Pigmentosa Clinical Trial
Official title:
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
Verified date | September 2016 |
Source | University of New Mexico |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This pilot study will evaluate the visual response to infrared (IR) in humans after dark
adaptation. The investigators plan to determine which wavelength and intensity the human eye
is most sensitive too, using a broad spectrum light source and wavelength-specific bandpass
filters. The investigators will then evaluate the electrophysiologic response in healthy
humans to IR, followed by studies in those with specific retinal diseases.
The long-term goal of this research is to better understand the role that IR plays in visual
function, and whether this can be manipulated to allow for vision in certain retinal
pathologies that result from loss of photoreceptor cells. The investigators central
objective is to test the electrophysiologic response to IR in the dark-adapted retinal and
visual pathways. The investigators central hypothesis is that IR evokes a visual response in
humans after dark adaptation, and the characteristics of this response suggest transient
receptor potential (TRP) channel involvement. The investigators rationale is that a better
understanding of how IR impacts vision may allow for an alternative mechanism for vision in
a number of diseases that cause blindness from the degradation or loss of function of
photoreceptor cells. The investigators will test the investigators hypothesis with the
following Aims:
Aim 1: To determine the optimal IR wavelength for visual perception in dark-adapted human
participants. The investigators hypothesize that the healthy human eye will detect IR
irradiation, with a maximum sensitivity at a specific wavelength. Using a broad-spectrum
light source with wavelength-specific bandpass filters, the spectral range of visual
perception to IR will be evaluated. The same will be done on colorblind participants.
Aim 2: To test the electrophysiologic response to IR in healthy humans after dark
adaptation. The investigators hypothesize that IR will elicit an amplitude change on
electroretinography (ERG) and visual evoked potential (VEP) responses after dark adaptation
in healthy human participants. Participants will be tested with both test modalities to
evaluate their response to IR.
Aim 3: To test the electrophysiologic response to IR after dark adaptation in humans with
certain retinal diseases. Participants with retinitis pigmentosa, age related macular
degeneration and congenital stationary night blindness, will be tested. Results will be
compared to baselines and to those of healthy participants. The investigators hypothesize
that there will be a response to IR on ERG and VEP, which will provide clues to the retinal
cell layer location of the response to IR and the nature of potential TRP channel
involvement.
Status | Completed |
Enrollment | 29 |
Est. completion date | August 2016 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Normal Vision - Colorblindness - Age related macular degeneration - Congenital Stationary Night Blindness Exclusion Criteria: - Diabetes - Heart disease - History of eye injury - History of eye trauma - History of eye disease except for those specified in the inclusion criteria - Pregnant women will also be excluded from Aim 2 and 3 - Persons with allergies to adhesives will be excluded from Aim 2 and 3 - Contact dermatitis - Documented adverse reaction to dilating drops - Documented adverse reaction to topical anesthetics - Vulnerable populations |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United States | University of New Mexico | Albuquerque | New Mexico |
Lead Sponsor | Collaborator |
---|---|
University of New Mexico |
United States,
Chow AY, Pardue MT, Chow VY, Peyman GA, Liang C, Perlman JI, Peachey NS. Implantation of silicon chip microphotodiode arrays into the cat subretinal space. IEEE Trans Neural Syst Rehabil Eng. 2001 Mar;9(1):86-95. — View Citation
Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004 Apr;122(4):564-72. Erratum in: Arch Ophthalmol. 2011 Sep;129(9):1188. — View Citation
Gekeler F, Shinoda K, Blatsios G, Werner A, Zrenner E. Scotopic threshold responses to infrared irradiation in cats. Vision Res. 2006 Feb;46(3):357-64. Epub 2005 Aug 2. — View Citation
Gracheva EO, Ingolia NT, Kelly YM, Cordero-Morales JF, Hollopeter G, Chesler AT, Sánchez EE, Perez JC, Weissman JS, Julius D. Molecular basis of infrared detection by snakes. Nature. 2010 Apr 15;464(7291):1006-11. doi: 10.1038/nature08943. Epub 2010 Mar 14. — View Citation
Kolb H. Simple Anatomy of the Retina. 2005 May 01 [updated 2012 Jan 31]. In: Kolb H, Fernandez E, Nelson R, editors. Webvision: The Organization of the Retina and Visual System [Internet]. Salt Lake City (UT): University of Utah Health Sciences Center; 1995-. Available from http://www.ncbi.nlm.nih.gov/books/NBK11533/ — View Citation
Numazaki M, Tominaga M. Nociception and TRP Channels. Curr Drug Targets CNS Neurol Disord. 2004 Dec;3(6):479-85. Review. — View Citation
Palczewska G, Vinberg F, Stremplewski P, Bircher MP, Salom D, Komar K, Zhang J, Cascella M, Wojtkowski M, Kefalov VJ, Palczewski K. Human infrared vision is triggered by two-photon chromophore isomerization. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5445-54. doi: 10.1073/pnas.1410162111. Epub 2014 Dec 1. — View Citation
Pardue MT, Ball SL, Hetling JR, Chow VY, Chow AY, Peachey NS. Visual evoked potentials to infrared stimulation in normal cats and rats. Doc Ophthalmol. 2001 Sep;103(2):155-62. — View Citation
Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012 May;96(5):614-8. doi: 10.1136/bjophthalmol-2011-300539. Epub 2011 Dec 1. Review. — View Citation
Sieving PA, Frishman LJ, Steinberg RH. Scotopic threshold response of proximal retina in cat. J Neurophysiol. 1986 Oct;56(4):1049-61. — View Citation
Stockman A, Sharpe LT, Fach C. The spectral sensitivity of the human short-wavelength sensitive cones derived from thresholds and color matches. Vision Res. 1999 Aug;39(17):2901-27. — View Citation
Wakabayashi K, Gieser J, Sieving PA. Aspartate separation of the scotopic threshold response (STR) from the photoreceptor a-wave of the cat and monkey ERG. Invest Ophthalmol Vis Sci. 1988 Nov;29(11):1615-22. — View Citation
White JP, Urban L, Nagy I. TRPV1 function in health and disease. Curr Pharm Biotechnol. 2011 Jan 1;12(1):130-44. Review. — View Citation
Wittenborn JS, Zhang X, Feagan CW, Crouse WL, Shrestha S, Kemper AR, Hoerger TJ, Saaddine JB; Vision Cost-Effectiveness Study Group. The economic burden of vision loss and eye disorders among the United States population younger than 40 years. Ophthalmology. 2013 Sep;120(9):1728-35. doi: 10.1016/j.ophtha.2013.01.068. Epub 2013 Apr 28. — View Citation
* Note: There are 14 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Electroretinography | Electroretinography response to infrared stimulus | Up to one year | No |
Other | Visual Evoke Potential | Visual Evoke Potential to infrared stimulus | Up to one year | No |
Primary | Visual perception to infrared | Ability to detect IR visually through subjective measurement | Up to one year | No |
Secondary | Description of color | Description of color to IR stimulus | Up to one year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 | |
Completed |
NCT04315025 -
Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa
|
Phase 1/Phase 2 |